Pay in 4 interest-free payments of $5.91 Learn more
Ships within 48 hours · Estimated delivery Aug 21 - Aug 26
Would you like to save this
This information helps your healthcare team identify patterns and determine whether symptoms relate to medication, diabetes control, or other factors
For context, semaglutide clinical trials showed approximately 15-17% body weight loss on average, and tirzepatide achieved 20-22% in some studies
Semaglutide (Ozempic, Wegovy, Rybelsus) by Novo Nordisk is the established standard of care, with FDA approval since 2017, proven cardiovascular benefit, and availability in both injectable and oral formulations
US$ 21.37
US$ 27.81
US$ 21.68
US$ 27.10
